Fusion polypeptide with multifunctional activity and application of fusion polypeptide

A fusion polypeptide and multifunctional technology, applied in fusion polypeptides, medical preparations containing active ingredients, hybrid peptides, etc., can solve the problems of high toxicity of chemical drugs, single pharmacological action, low safety, etc. The effect of reducing expression content and high safety

Active Publication Date: 2019-10-25
NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] Most of the existing drugs for the treatment of fibrosis are chemical drugs, which have problems such as high toxicity, low safety, and single pharmacological effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion polypeptide with multifunctional activity and application of fusion polypeptide
  • Fusion polypeptide with multifunctional activity and application of fusion polypeptide
  • Fusion polypeptide with multifunctional activity and application of fusion polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1, pulmonary fibrosis animal model

[0058] Experimental animals and materials:

[0059] 1. Experimental animals:

[0060] Source, species, and strain: clean SD rats, provided by the Comparative Medicine Center of Yangzhou University (experimental animal production license: SCXK (Su) 2012-0004); experimental animal use license: SYXK (Su) 2012-0035) .

[0061] Weight: 180-200g at the time of purchase, 190-210g at the beginning of modeling, and 180-200g at the beginning of administration.

[0062] Gender: male.

[0063] 2. Experimental materials:

[0064]

[0065] 3. Experimental method:

[0066] SD rats were anesthetized by intraperitoneal injection of 1 mL / 100 g and 4% chloral hydrate. After the rats were anesthetized, the rats were fixed, and the necks of the rats were disinfected with 75% alcohol cotton. Cut the rat neck skin longitudinally with scissors, and bluntly tear the fascia and muscles longitudinally with forceps to expose the trachea. A ...

Embodiment 2

[0079] Embodiment 2, liver fibrosis animal model

[0080] 1. Experimental animals:

[0081] Source, species, strain: SPF grade, SD rats, provided by Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd. (Experimental animal license: SCXK (Shanghai) 2013-0016)

[0082] Weight: 180-200g at the time of purchase, 200-220g at the beginning of modeling

[0083] Gender: Male.

[0084] 2. Experimental materials:

[0085]

[0086] 3. Experimental method

[0087] Divide the male SD rats into the following groups, see the table below for grouping, 10 rats in each group, and model them. Except for the blank group, the rest of the groups are treated twice a week with 40% CCl 4 Intraperitoneal injection, the first injection was 3 mL / kg, followed by administration at 2 mL / kg for a total of 8 weeks, and a total of 16 injections were used to induce hepatic fibrosis. Since the fourth intraperitoneal injection of CCl 4 After that, polypeptide therapy was given on the next day, administered b...

Embodiment 3

[0097] Embodiment 3, establishment of renal fibrosis model

[0098] 1. Experimental animals

[0099] Clean-grade male SD rats were purchased from Nanjing Qinglongshan Animal Farm, with a body weight of 180-200g when purchased, 190-210g when the model was started, and 180-200g when the drug was started.

[0100] 2. Experimental materials:

[0101] Normal saline manufacturer: Anhui Shuanghe Pharmaceutical Co., Ltd.

[0102] Rat TGF-β1 ELISA Kit Manufacturer: Tianjin Anoricang Biotechnology Co., Ltd.

[0103] Alkaline HYP Kit Manufacturer: Nanjing Jiancheng

[0104] 3. Experimental method

[0105] To establish an animal model of renal fibrosis, SD rats were anesthetized with 4% chloral hydrate, intraperitoneally injected with 1mL / 100g, fixed on the operating board, and the operating area was sterilized for later use, about 3- Cut open the abdominal cavity at 4 mm, and the surgical team treated the left kidney and ureter, ligated and separated the ureter near the lower pole o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a fusion polypeptide with multifunctional activity. The fusion polypeptide with multifunctional activity is characterized in that the polypeptide comprises any one of the following structural domains: Pro-Arg-Cys-X-Y-Gly-Glu, wherein X is Trp or Tyr and Y is Arg or Cys; Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. Various fibrotic diseases and symptoms can be treated, including lung fibrosis, liver fibrosis, skin fibrosis, kidney fibrosis and myocardial fibrosis, as well as lung tissue disorders.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and more specifically, relates to a method for preventing or treating various fibrotic diseases and conditions. muscle fibrosis. Background technique [0002] Tissue fibrosis (fibrosis) is a kind of organ tissue parenchymal cell reduction, fibrous connective tissue hyperplasia disease, continuous development can lead to organ structure destruction and functional decline, eventually failure, seriously threatening the health of patients. Worldwide, tissue and organ fibrosis is the main cause of disability and death in many diseases. [0003] In the process of tissue fibrosis, fibroblasts and myofibroblasts are the key effector cells of tissue fibrosis, and these effector cells can release a large amount of collagen components that constitute the ECM, such as type I and type III collagen. A variety of cytokines are also involved in the process of fibrosis, the most critical of which is transformi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K19/00A61K38/16A61P11/00A61P1/16A61P13/12A61P9/00A61P17/00A61P31/04A61P31/12A61P31/10A61P33/02
CPCC07K7/06C07K14/00A61P11/00A61P1/16A61P13/12A61P9/00A61P17/00A61P31/04A61P31/12A61P31/10A61P33/02C07K2319/00A61K38/00A61K38/16C07K14/8146
Inventor 康志安
Owner NANJING ANJI BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap